Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus raises 2025 revenue guidance, cuts operating earnings outlook after Q2 results

Mixed Impact 4 of 5 guidance Written later

Supernus reported second-quarter 2025 total revenues of $165.5 million, down 2% from $168.3 million a year earlier, while diluted earnings per share rose to $0.40 from $0.36 and net earnings were $22.5 million. It raised full-year 2025 revenue guidance to $670 million-$700 million and moved its GAAP operating earnings guidance to a loss of $70 million-$80 million, citing the Sage Therapeutics acquisition completed July 31, 2025. For shareholders, quarterly profit improved, but revenue slipped and the GAAP operating outlook worsened.

Key points

  • Q2 2025 total revenues were $165.5 million, versus $168.3 million in Q2 2024; Qelbree net sales rose 31% to $77.6 million.
  • Q2 2025 net earnings were $22.5 million, or $0.40 per diluted share, versus $0.36 a year earlier; six-month diluted EPS was $0.19 versus $0.36.
  • Full-year 2025 total revenue guidance is $670 million-$700 million, up from $600 million-$630 million.
  • Full-year 2025 GAAP operating earnings (loss) guidance is $(70) million to $(80) million, down from $(15) million to $10 million.

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECAug 5, 2025, 4:18 PM ET
Accession number0001356576-25-000053

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.